Avalo Therapeutics (AVTX) Return on Invested Capital (2017 - 2026)
Avalo Therapeutics posted quarterly Return on Invested Capital of 0.01% for Q1 2026, down 1.0% year-on-year from 0.01% in Q1 2025, and down 25.19% on a QoQ basis from 0.01% in Q4 2025.
Avalo Therapeutics (AVTX) has 10 years of Return on Invested Capital data on file, last reported at 0.01% in Q1 2026.
- For the quarter ending Q1 2026, Return on Invested Capital fell 1.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (down 1.0% YoY), and the FY2025 full-year result was 0.01%, changed 0.0% from the prior year.
- Return on Invested Capital for Q1 2026 stood at 0.01%, down from 0.01% in the prior quarter.
- Across five years, Return on Invested Capital topped out at 0.12% in Q3 2022 and bottomed at 3.43% in Q2 2022.
- The 5-year median for Return on Invested Capital is 0.01% (2025), against an average of 0.21%.
- The widest annual swing landed in 2022, when Return on Invested Capital plunged 340 bps; it then jumped 346 bps in 2023.
- A 5-year view of Return on Invested Capital shows it stood at 0.06% in 2022, then tumbled by 143 bps to 0.02% in 2023, then surged by 64 bps to 0.01% in 2024, then increased by 6 bps to 0.01% in 2025, then decreased by 25 bps to 0.01% in 2026.
- The last three Return on Invested Capital figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -0.01% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.00% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -0.01% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.00% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.01% |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | -0.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.01% |
| Dec 31, 2025 | -0.01% |
| Sep 30, 2025 | -0.01% |
| Jun 30, 2025 | -0.01% |
| Mar 31, 2025 | 0.00% |
| Dec 31, 2024 | -0.01% |
| Sep 30, 2024 | -0.17% |
| Jun 30, 2024 | 0.01% |
| Mar 31, 2024 | 0.01% |
| Dec 31, 2023 | -0.02% |
| Sep 30, 2023 | -0.07% |
| Jun 30, 2023 | 0.03% |
| Mar 31, 2023 | 0.03% |
| Dec 31, 2022 | 0.06% |
| Sep 30, 2022 | 0.12% |
| Jun 30, 2022 | -3.43% |
| Mar 31, 2022 | -0.05% |
| Dec 31, 2021 | -0.03% |
| Sep 30, 2021 | -0.03% |
| Jun 30, 2021 | -0.03% |
| Mar 31, 2021 | -0.02% |
| Dec 31, 2020 | -0.02% |
| Sep 30, 2020 | -0.01% |
| Jun 30, 2020 | -0.01% |
| Mar 31, 2020 | -0.02% |
| Dec 31, 2019 | -0.01% |
| Sep 30, 2019 | -0.01% |
| Jun 30, 2019 | -0.02% |
| Mar 31, 2019 | -0.02% |
| Dec 31, 2018 | -0.02% |
| Sep 30, 2018 | -0.02% |
| Jun 30, 2018 | 0.00% |
| Mar 31, 2018 | 0.00% |
| Dec 31, 2017 | 0.00% |
| Sep 30, 2017 | 0.01% |